This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Q4 Earnings Miss, COVID Therapies Aid Sales
by Zacks Equity Research
Eli Lilly (LLY) misses earnings estimates in the fourth quarter while revenues beat the same. Stock down in pre-market trading.
Merck (MRK) Q4 Earnings & Sales Beat, COVID Drug Adds $952M
by Zacks Equity Research
Merck (MRK) beats Q4 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.
Roche's (RHHBY) 2021 Earnings, Sales Grow on COVID-19 Tests
by Zacks Equity Research
Roche (RHHBY) performance in the fourth quarter and 2021 was encouraging, driven by demand for COVID-19 tests and recovery in pharma sales. However, sales are expected to slow down in 2022.
Incyte (INCY) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.
Best Growth Stocks to Buy for February 3rd
by Zacks Equity Research
CROX, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 3, 2022
5 Corporate Bigwigs to Buy Ahead of Earnings Next Week
by Nalak Das
Five corporate bigwigs will report fourth-quarter 2021 earnings results next week. These are: HAS, PFE, TWLO, CDW and NLY.
Zacks.com featured highlights include: Pfizer, The Kroger Co., Archer-Daniels-Midland Co., HP Inc. and Jones Lang LaSalle Inc
by Zacks Equity Research
Pfizer, The Kroger Co., Archer-Daniels-Midland Co., HP Inc. and Jones Lang LaSalle Inc are highlighted in this Screen of the Week article.
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Is a Beat Likely for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.
Is a Beat Likely for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing
by Zacks Equity Research
Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.
5 Cheap Dividend Growth Stocks to Bet Amid Volatility
by Sweta Killa
Pfizer (PFE), Kroger (KR), Archer-Daniels (ADM), HP Inc. (HPQ) and Jones Lang (JLL) seems compelling cheap picks amid volatility.
Best Growth Stocks to Buy for February 2nd
by Zacks Equity Research
PFE, TOL, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 2, 2022
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $53.07, marking a +0.72% move from the previous day.
Moderna (MRNA) Up on Its COVID Vaccine's Receipt of Full FDA Nod
by Zacks Equity Research
The FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab
by Zacks Equity Research
After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.
Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis
by Zacks Equity Research
Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.
Will Merck (MRK) Succeed in Beating Q4 Earnings Expectations?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q4 earnings.
Best Growth Stocks to Buy for February 1st
by Zacks Equity Research
CROX, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 1, 2022
Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel
by Zacks Equity Research
Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.
Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.
Pfizer (PFE) Lorviqua Gets EU Nod for First-Line Lung Cancer
by Zacks Equity Research
The European Commission approves label expansion of Pfizer's (PFE) Lorviqua as a first-line treatment for ALK-positive non-small cell lung cancer.
Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema
by Zacks Equity Research
While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.
AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery
by Zacks Equity Research
AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.